Early and accurate diagnosis of MS is probably the most important component of MS treatment — getting patients on effective therapies as quickly as possible has a dramatic effect on…
Read More
You're Reading:
About the Author
Pete Broderick is the Marketing and Communications Manager at the Rocky Mountain MS Center. He is also the editor and one of the primary writers for InforMS Magazine.
More From This Issue:
InforMS: Winter 2024
Progress & Promise: Exploring the Latest Developments in Multiple Sclerosis Research
Research is the driver of progress in MS care and treatment. In this issue, we’ll take you inside some of the most promising innovations transforming the MS landscape. We begin...
InforMS: Winter 2024
CAR T-Cell Therapy: A New Frontier for Treating Autoimmune Diseases
Our immune system is a vast and powerful network, filled with specialized cells and proteins designed to protect us from infections and diseases. However, in autoimmune diseases like MS, some...
InforMS: Winter 2024
BTK Inhibitors in MS Treatment: Recent Clinical Trial Results and Key Takeaways
A new class of treatment approaches for MS being studied are Bruton’s Tyrosine Kinase (BTK) inhibitors, or BTKi. Designed as once-daily oral enzyme inhibitors, BTK inhibitors target specific immune cells...
InforMS: Winter 2024
A Conversation with Dr. Enrique Alvarez
New Medical Director on What’s Next in MS InforMS Magazine is excited to welcome the Rocky Mountain MS Center’s new Medical Director, Dr. Enrique Alvarez. While the title may be...
InforMS: Winter 2024
Revamping the Diagnosis Criteria for Multiple Sclerosis
Proposed Changes to How We Determine Who Has MS At the ECTRIMS meeting in September, there was a presentation on proposed updates to the 2017 McDonald criteria to diagnose MS....
InforMS: Winter 2024